Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03736720
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:55.172650+00:00
Published At
2023-12-19T00:00:00+00:00
Record Updated At
2025-01-30
Results Posted At
2023-12-19
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Locally Advanced Digestive System Neuroendocrine Carcinoma", "Locally Advanced Pancreatic Neuroendocrine Carcinoma", "Metastatic Digestive System Neuroendocrine Carcinoma", "Metastatic Pancreatic Neuroendocrine Carcinoma", "Refractory Digestive System Neuroendocrine Carcinoma", "Refractory Pancreatic Neuroendocrine Carcinoma", "Unresectable Digestive System Neuroendocrine Carcinoma", "Unresectable Pancreatic Neuroendocrine Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-01-30"
protocolSection.identificationModule.nctId
"NCT03736720"
protocolSection.identificationModule.officialTitle
"Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-12-19"

Study condition terms

  • Locally Advanced Digestive System Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Pancreatic Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Digestive System Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Pancreatic Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Refractory Digestive System Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Refractory Pancreatic Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Unresectable Digestive System Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Unresectable Pancreatic Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.